- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 20-F Annual report (foreign)
- 1.2 Amended and Restated By-law Number and Bylaw
- 2.1 Description of Securities
- 4.2 Arrangement Agreement
- 4.3 Exclusive Intellectual Property License Agreement
- 4.4 Warrant Certificate
- 4.5 Loan Agreement and Security Agreement
- 8.1 List of Subsidiaries
- 12.1 Certification
- 12.2 Certification
- 13.1 Certification
- 13.2 Certification
- 15.1 Managements Discussion and Analysis
- 15.2 Consent of Independent Auditor
- 97.1 Clawback Policy
- Download Excel data file
- View Excel data file
EXHIBIT 13.2
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 20-F of FSD Pharma Inc. (the "Company") for the period ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Nathan Coyle, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
(2) | The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: April 1, 2024 | By: | /s/ Nathan Coyle |
|
Nathan Coyle |
| ||
Chief Financial Officer (Principal Financial Officer) |
|
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.